JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:2049-2056, doi:10.1016/j.jacc.2006.01.057 (Published online 20 April 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Online Appendix
Right arrow All Versions of this Article:
j.jacc.2006.01.057v1
47/10/2049    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (74)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barst, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barst, R. J.

CLINICAL RESEARCH: PULMONARY HYPERTENSION

Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan

Robyn J. Barst, MD*,1,*, David Langleben, MD{dagger},1, David Badesch, MD{ddagger},1, Adaani Frost, MD§,1, E. Clinton Lawrence, MD||,1, Shelley Shapiro, MD,1, Robert Naeije, MD#,1, Nazzareno Galie, MD**,1 on behalf of the STRIDE-2 Study Group

* Department of Pediatrics, Columbia University Medical Center, New York, New York
{dagger} Jewish General Hospital, Montreal, Quebec, Canada
{ddagger} University of Colorado, Denver, Colorado
§ Baylor College of Medicine, Houston, Texas
|| McKelvey Lung Transplantation Center, Emory University, Atlanta, Georgia
University of Southern California, Los Angeles, California
# Erasmus University, Brussels, Belgium
** Institute of Cardiology, University of Bologna, Bologna, Italy.

Manuscript received September 20, 2005; revised manuscript received December 23, 2005, accepted January 9, 2006.

* Reprint requests and correspondence: Dr. Robyn J. Barst, Columbia University College of Physicians and Surgeons, 3959 Broadway, BHN 2-255, New York, New York 10032. (Email: rjb3{at}columbia.edu).

OBJECTIVES: We sought to determine the optimal dose of the selective endothelin A (ETA) receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for observation only, an open-label (OL) bosentan arm was included.

BACKGROUND: Endothelin is a mediator of PAH. In a preliminary PAH study, the selective ETA receptor antagonist sitaxsentan improved six-min walk (6MW) distance, World Health Organization (WHO) functional class (FC), and hemodynamics.

METHODS: In this double-blind, placebo-controlled 18-week study, 247 PAH patients (idiopathic, or associated with connective tissue disease or congenital heart disease) were randomized; 245 patients were treated: placebo (n = 62), sitaxsentan 50 mg (n = 62) or 100 mg (n = 61), or OL (6MW tests, Borg dyspnea scores, and WHO FC assessments third-party blind) bosentan (n = 60). The primary end point was change in 6MW distance from baseline to week 18. Secondary end points included change in WHO FC, time to clinical worsening, and change in Borg dyspnea score.

RESULTS: At week 18, patients treated with sitaxsentan 100 mg had an increased 6MW distance compared with the placebo group (31.4 m, p = 0.03), and an improved WHO FC (p = 0.04). The placebo-subtracted treatment effect for sitaxsentan 50 mg was 24.2 m (p = 0.07) and for OL bosentan, 29.5 m (p = 0.05). The incidence of elevated hepatic transaminases (>3x the upper limit of normal) was 6% for placebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100 mg, and 11% for bosentan.

CONCLUSIONS: Treatment with the selective ETA receptor antagonist sitaxsentan, orally once daily at a dose of 100 mg, improves exercise capacity and WHO FC in PAH patients, with a low incidence of hepatic toxicity.

Abbreviations and Acronyms
  ALT = alanine aminotransferase
  ANCOVA = analysis of covariance
  AST = aspartate aminotransferase
  DSMB = Data Safety Monitoring Board
  ET = endothelin
  FC = functional class
  INR = international normalized ratio
  ITT = intent-to-treat
  OL = open label
  PAH = pulmonary arterial hypertension
  6MW = six-min walk
  STRIDE = Sitaxsentan To Relieve ImpaireD Exercise study
  ULN = upper limit of normal
  WHO = World Health Organization




This article has been cited by other articles:


Home page
 ChestHome page
R. L. Benza, R. J. Barst, N. Galie, A. Frost, R. E. Girgis, K. B. Highland, C. Strange, C. M. Black, D. B. Badesch, L. Rubin, et al.
Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension: A 1-Year, Prospective, Open-Label Observation of Outcome and Survival
Chest, October 1, 2008; 134(4): 775 - 782.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Eur. Heart J., August 2, 2008; 29(16): 1936 - 1948.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Respiratory DiseaseHome page
K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert
Review: Therapeutic advances in pulmonary arterial hypertension
Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 249 - 265.
[Abstract] [PDF]

Home page
 J Clin PharmacolHome page
R. Frey, W. Muck, S. Unger, U. Artmeier-Brandt, G. Weimann, and G. Wensing
Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers
J. Clin. Pharmacol., August 1, 2008; 48(8): 926 - 934.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Galie, H. Olschewski, R. J. Oudiz, F. Torres, A. Frost, H. A. Ghofrani, D. B. Badesch, M. D. McGoon, V. V. McLaughlin, E. B. Roecker, et al.
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Circulation, June 10, 2008; 117(23): 3010 - 3019.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J Avouac, J Wipff, A Kahan, and Y Allanore
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials
Ann Rheum Dis, June 1, 2008; 67(6): 808 - 814.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. E. Wrishko, J. Dingemanse, A. Yu, C. Darstein, D. L. Phillips, and M. I. Mitchell
Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects
J. Clin. Pharmacol., May 1, 2008; 48(5): 610 - 618.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. M. Chin and L. J. Rubin
Pulmonary arterial hypertension.
J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1527 - 1538.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Heart, March 1, 2008; 94(Suppl_1): i1 - i41.
[Full Text] [PDF]

Home page
 ThoraxHome page
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Dupuis and M. M. Hoeper
Endothelin receptor antagonists in pulmonary arterial hypertension
Eur. Respir. J., February 1, 2008; 31(2): 407 - 415.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. Kamezaki, H. Tasaki, K. Yamashita, M. Tsutsui, S. Koide, S. Nakata, A. Tanimoto, M. Okazaki, Y. Sasaguri, T. Adachi, et al.
Gene Transfer of Extracellular Superoxide Dismutase Ameliorates Pulmonary Hypertension in Rats
Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 219 - 226.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
R. E Girgis, A. E Frost, N. S Hill, E. M Horn, D. Langleben, V. V McLaughlin, R. J Oudiz, I. M Robbins, J. R Seibold, S. Shapiro, et al.
Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease
Ann Rheum Dis, November 1, 2007; 66(11): 1467 - 1472.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. M. Patel, D. J. Lederer, A. C. Borczuk, and S. M. Kawut
Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Chest, September 1, 2007; 132(3): 998 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. L. Helman Jr, A. W. Brown, J. L. Jackson, and A. F. Shorr
Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials
Chest, September 1, 2007; 132(3): 764 - 772.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. B. Badesch, S. H. Abman, G. Simonneau, L. J. Rubin, and V. V. McLaughlin
Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines
Chest, June 1, 2007; 131(6): 1917 - 1928.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
N. J. Benedict
Sitaxsentan in the management of pulmonary arterial hypertension
Am. J. Health Syst. Pharm., February 15, 2007; 64(4): 363 - 368.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
E. T Wittbrodt and A. Abubakar
Sitaxsentan for Treatment of Pulmonary Hypertension
Ann. Pharmacother., January 1, 2007; 41(1): 100 - 105.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Gomberg-Maitland
Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better?
Eur. Respir. J., October 1, 2006; 28(4): 683 - 686.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
O. Distler and A. Pignone
Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment
Rheumatology, October 1, 2006; 45(suppl_4): iv22 - iv25.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. Riemekasten and C. Sunderkotter
Vasoactive therapies in systemic sclerosis
Rheumatology, October 1, 2006; 45(suppl_3): iii49 - iii51.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. J. Rubin
Endothelin-1 and the Pulmonary Vascular Response to Altitude: A New Therapeutic Target?
Circulation, September 26, 2006; 114(13): 1350 - 1351.
[Full Text] [PDF]

Home page
 CirculationHome page
V. V. McLaughlin and M. D. McGoon
Pulmonary Arterial Hypertension
Circulation, September 26, 2006; 114(13): 1417 - 1431.
[Full Text] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.